I am an investigator and psychometrician focusing on the application of patient reported outcomes (PROs) in patient focused drug development and in clinical monitoring to optimize patient management. In this capacity, I work extensively on establishing evidence to support PROs as clinical outcome assessments (COAs) to implement in drug trials, with a specific focus in kidney disease and oncology. I also have a line of research examining new tools and methods to quantify and manage drug intolerability across multiple therapeutic areas, including oncology and solid organ transplantation.